Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remogliflozin etabonate - Avolynt/Kissei-Pharmaceutical

Drug Profile

Remogliflozin etabonate - Avolynt/Kissei-Pharmaceutical

Alternative Names: 189075; BHV 091009; GSK 189075; KGT-1681; Remo; Remogliflozin; Remozen; Zucator

Latest Information Update: 15 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Avolynt; BHV Pharma; GlaxoSmithKline; Glenmark Pharmaceuticals Ltd; Kissei Pharmaceutical
  • Class Antihyperglycaemics; Glucosides; Hepatoprotectants; Pyrans; Pyrazoles
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis
  • Discontinued Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 11 Jul 2019 Glenmark and Torrent signs sub-licensing agreement to co-market Remogliflozin etabonate in India
  • 03 May 2019 Discontinued - Phase-I for Obesity in USA (PO) (Avolynt pipeline, May 2019)
  • 03 May 2019 Discontinued - Phase-I for Type 1 diabetes mellitus in USA (PO) (Avolynt pipeline, May 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top